Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aarhus University, Denmark
Reports from Aarhus University, Department of Clinical Biochemistry highlight recent research in life sciences therapy
November 7th, 2006
Researchers detail in "The chemotherapeutic agent VP16 increases the stability of HB-EGF mRNA by a mechanism involving the 3'-UTR," new data in life sciences. According to a study from Denmark, "VP16 is a chemotherapeutic agent that introduces DNA damage. We demonstrate that cellular stress induced by VP16 in the human cervix cancer cell line HeLa increases the HB-EGF (heparin binding epidermal growth factor like growth factor) mRNA level dose dependently." "Maximal induction (10-fold) was observed at 20-40 microM VP16. Increased HB-EGF peptide levels accompanied the increase in HB-EGF mRNA. We investigated the molecular mechanism involved in HB-EGF mRNA induction by...
Source: Drug Law Weekly (2006-11-07)
|
